Enanta Pharmaceuticals (NASDAQ:ENTA) has done better than expected with its first set of annual results as a publicly traded entity, weighing in with both its fiscal Q4 and full-year 2013 figures. For the quarter, the biotech firm posted revenue of $1.35 million, down from the $1.86 million in the same period the previous year. Attributable net loss narrowed over that span of time to $4.44 million ($0.25 per diluted share), from Q4 2012's $5.38 million ($4.78).
For the full year, the top line came in at $32.05 million, against the prior year's $41.71 million. Meanwhile, attributable net loss was $6.57 million ($0.67 per diluted share) compared with a profit of $1.37 million ($1.13) in 2012.
In spite of the losses, Enanta sounded an optimistic note in its earnings release. It quoted CEO Jay Luly as pointing out that "we ended the year with three [Hepatitis C] compounds in the clinic and we have progressed our internal programs and pipeline candidates."
According to Bloomberg Businessweek, the three analysts tracking the firm had collectively been expecting a per-share loss of $0.31 for Q4, and $1.78 for the fiscal year.
The company's stock has been popular since making its debut on the market this past March. Its IPO priced at $14 per share; on Monday, the stock closed at $24.84.